ArticleCurrent microbiology2026
An Enzymatic Recombinase Amplification Coupled Lateral Flow Assay for Rapid, Visual, and Cost-Effective Detection of Bordetella pertussis.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bordetella pertussis, the causative agent of pertussis, is a highly contagious respiratory pathogen. Rapid and reliable diagnostics are essential for early detection and disease control. Here, we developed an enzymatic recombinase amplification–lateral flow dipstick (ERA-LFD) assay targeting the IS1663 gene of B. pertussis. The assay achieves high sensitivity with detection limit of 10 copies/µL, and analytical specificity reached 100%. It was performed at 32 ℃ for 15 min, with visual results obtainable within 20 min. Clinical evaluation of 50 nasopharyngeal swab samples demonstrated a sensitivity of 96.6%, specificity of 100%, negative predictive value of 95.2%, and positive predictive value of 100%, showing excellent agreement with quantitative PCR (Kappa = 0.96). These results indicate that the ERA-LFD assay is a rapid, reliable, and field-deployable tool for B. pertussis on-site detection, particularly suitable for point-of-care testing in resource-limited settings.
Indexed as
Identifiers
41879849What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.